220 related articles for article (PubMed ID: 27588398)
1. ABCB1 and ABCC11 confer resistance to eribulin in breast cancer cell lines.
Oba T; Izumi H; Ito KI
Oncotarget; 2016 Oct; 7(43):70011-70027. PubMed ID: 27588398
[TBL] [Abstract][Full Text] [Related]
2. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
[TBL] [Abstract][Full Text] [Related]
3. ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells.
Honorat M; Mesnier A; Vendrell J; Guitton J; Bieche I; Lidereau R; Kruh GD; Dumontet C; Cohen P; Payen L
Endocr Relat Cancer; 2008 Mar; 15(1):125-38. PubMed ID: 18310281
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
[TBL] [Abstract][Full Text] [Related]
5. ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report.
Sakil HAM; Stantic M; Wolfsberger J; Brage SE; Hansson J; Wilhelm MT
Cell Oncol (Dordr); 2017 Dec; 40(6):631-638. PubMed ID: 28677036
[TBL] [Abstract][Full Text] [Related]
6. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
[TBL] [Abstract][Full Text] [Related]
7. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
8. Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Moriya T
Breast Cancer; 2016 May; 23(3):425-36. PubMed ID: 25552385
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines.
Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Fujita H; Takashima T; Shibutani M; Amano R; Tomita S; Hirakawa K; Ohira M
Anticancer Res; 2019 Aug; 39(8):4031-4041. PubMed ID: 31366485
[TBL] [Abstract][Full Text] [Related]
10. Modulation of ABCC1 and ABCG2 proteins by ouabain in human breast cancer cells.
DA Silva VA; DA Silva KA; Delou JM; DA Fonseca LM; Lopes AG; Capella MA
Anticancer Res; 2014 Mar; 34(3):1441-8. PubMed ID: 24596392
[TBL] [Abstract][Full Text] [Related]
11. Eribulin mesylate-induced c-Fos upregulation enhances cell survival in breast cancer cell lines.
Tanaka S; Ishii T; Sato F; Toi M; Itou J
Biochem Biophys Res Commun; 2020 May; 526(1):154-157. PubMed ID: 32201082
[TBL] [Abstract][Full Text] [Related]
12. Eribulin upregulates miR-195 expression and downregulates Wnt3a expression in non-basal-like type of triple-negative breast cancer cell MDA-MB-231.
Furuya K; Sasaki A; Tsunoda Y; Tsuji M; Udaka Y; Oyamada H; Tsuchiya H; Oguchi K
Hum Cell; 2016 Apr; 29(2):76-82. PubMed ID: 26573286
[TBL] [Abstract][Full Text] [Related]
13. Enhancing chemosensitivity in ABCB1- and ABCG2-overexpressing cells and cancer stem-like cells by an Aurora kinase inhibitor CCT129202.
Cheng C; Liu ZG; Zhang H; Xie JD; Chen XG; Zhao XQ; Wang F; Liang YJ; Chen LK; Singh S; Chen JJ; Talele TT; Chen ZS; Zhong FT; Fu LW
Mol Pharm; 2012 Jul; 9(7):1971-82. PubMed ID: 22632055
[TBL] [Abstract][Full Text] [Related]
14. Stathmin dynamics modulate the activity of eribulin in breast cancer cells.
Yoshie M; Ishida A; Ohashi H; Nakachi N; Azumi M; Tamura K
Pharmacol Res Perspect; 2021 Aug; 9(4):e00786. PubMed ID: 34176226
[TBL] [Abstract][Full Text] [Related]
15. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.
Aldonza MB; Hong JY; Alinsug MV; Song J; Lee SK
Oncotarget; 2016 Jun; 7(23):34395-419. PubMed ID: 27284014
[TBL] [Abstract][Full Text] [Related]
16. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Li W; Zhai B; Zhi H; Li Y; Jia L; Ding C; Zhang B; You W
Tumour Biol; 2014 Sep; 35(9):8883-91. PubMed ID: 24894670
[TBL] [Abstract][Full Text] [Related]
17. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu LW
Biochem Pharmacol; 2015 Sep; 97(1):27-37. PubMed ID: 26206183
[TBL] [Abstract][Full Text] [Related]
18. ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel.
Kathawala RJ; Wang YJ; Shukla S; Zhang YK; Alqahtani S; Kaddoumi A; Ambudkar SV; Ashby CR; Chen ZS
Chin J Cancer; 2015 Mar; 34(3):115-20. PubMed ID: 25962593
[TBL] [Abstract][Full Text] [Related]
19. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter.
Qiu JG; Zhang YJ; Li Y; Zhao JM; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Yang Y; Zheng DW; Chen Y; Wei MN; Shi Z
Oncotarget; 2015 Jun; 6(17):15494-509. PubMed ID: 25915534
[TBL] [Abstract][Full Text] [Related]
20. Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters.
Němcová-Fürstová V; Kopperová D; Balušíková K; Ehrlichová M; Brynychová V; Václavíková R; Daniel P; Souček P; Kovář J
Toxicol Appl Pharmacol; 2016 Nov; 310():215-228. PubMed ID: 27664577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
